Fineline Cube

Follow:
14486 Articles
GE Healthcare Unveils Invenia ABUS Premium for Enhanced Dense Breast Screening
CompanyMedical Device

GE Healthcare Unveils Invenia ABUS Premium for Enhanced Dense Breast Screening

Daiichi Sankyo Launches Datroway in Japan for HR Positive, HER2 Negative Breast Cancer
CompanyDrug

Daiichi Sankyo Launches Datroway in Japan for HR Positive, HER2 Negative Breast Cancer

Porton Pharma Solutions' Porton Advanced Partners with Eureka Therapeutics on T-Cell Therapies
CompanyDeals

Porton Pharma Solutions’ Porton Advanced Partners with Eureka Therapeutics on T-Cell Therapies

Triastek's 3D-Printed T20G Receives US Clinical Approval for NOAC Treatment
CompanyDrug

Triastek’s 3D-Printed T20G Receives US Clinical Approval for NOAC Treatment

Johnson & Johnson's Tremfya Gains FDA Approval for Crohn's Disease Treatment
CompanyDrug

Johnson & Johnson’s Tremfya Gains FDA Approval for Crohn’s Disease Treatment

Menarini Group Partners with VisualDx to Enhance BPDCN Identification Using AI/ML Tools
CompanyDeals

Menarini Group Partners with VisualDx to Enhance BPDCN Identification Using AI/ML Tools

Elevation Oncology Halts EO-3021 Development After Poor Phase 1 Data
CompanyDrug

Elevation Oncology Halts EO-3021 Development After Poor Phase 1 Data

Changchun High & New Technology Industries Receives US Trial Approval for GenSci120 in Rheumatoid Arthritis
CompanyDrug

Changchun High & New Technology Industries Receives US Trial Approval for GenSci120 in Rheumatoid Arthritis

Novartis' Fabhalta Approved by FDA for C3 Glomerulopathy Treatment
CompanyDrug

Novartis’ Fabhalta Approved by FDA for C3 Glomerulopathy Treatment

Sino Biopharmaceutical's 2024 Revenue Up 10.2% on Strong Innovative Drug Sales
Company

Sino Biopharmaceutical’s 2024 Revenue Up 10.2% on Strong Innovative Drug Sales

Arcutis Biotherapeutics' Zoryve Cream Nears FDA Approval for Pediatric Atopic Dermatitis
CompanyDrug

Arcutis Biotherapeutics’ Zoryve Cream Nears FDA Approval for Pediatric Atopic Dermatitis

Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager
CompanyDeals

Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager